SCHEMBL2175877

SCHEMBL2175877

C[C@]12C[C@H](O)[C@H]3[C@@H](C[C@@H](O)C4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.72
CYP3A4 P08684 7/20 0.72
HIF1A Q16665 6/20 0.72
LMNA P02545 4/20 0.72
CYP2C9 P11712 3/20 0.72
NR3C2 P08235 3/20 0.72
SHBG P04278 3/20 0.72
SERPINA6 P08185 3/20 0.72
HSD17B10 Q99714 3/20 0.72
MAPT P10636 2/20 0.72
MAPK1 P28482 2/20 0.72
TSHR P16473 2/20 0.72
BLM P54132 1/20 0.72
SLC22A2 O15244 1/20 0.72
SLC22A1 O15245 1/20 0.72
SLC22A3 O75751 1/20 0.72
NFKB1 P19838 1/20 0.72
THPO P40225 1/20 0.72
MTOR P42345 1/20 0.72
SIGMAR1 Q99720 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL137293 1.00 SMN1; SMN2 (0.72) SMN1; SMN2CYP3A4HIF1ALMNACYP2C9
SCHEMBL8668291 0.91 SMN1; SMN2 (0.80) SMN1; SMN2CYP3A4HIF1ALMNACYP2C9
SCHEMBL8668298 0.91 SMN1; SMN2 (0.80) SMN1; SMN2CYP3A4HIF1ALMNACYP2C9
SCHEMBL13449676 0.90 SMN1; SMN2 (0.70) SMN1; SMN2CYP3A4HIF1ALMNACYP2C9
SCHEMBL11125549 0.86 SMN1; SMN2 (0.62) SMN1; SMN2CYP3A4HIF1ALMNACYP2C9
SCHEMBL11125553 0.86 SMN1; SMN2 (0.62) SMN1; SMN2CYP3A4HIF1ALMNACYP2C9
SCHEMBL11125542 0.85 SMN1; SMN2 (0.61) SMN1; SMN2CYP3A4HIF1ALMNACYP2C9
SCHEMBL4110734 0.84 CYP3A4 (0.70) SMN1; SMN2CYP3A4HIF1ALMNACYP2C9
SCHEMBL13752943 0.84 CYP3A4 (0.70) SMN1; SMN2CYP3A4HIF1ALMNACYP2C9
SCHEMBL4110739 0.84 CYP3A4 (0.70) SMN1; SMN2CYP3A4HIF1ALMNACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4149497-A1 NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS Platelet Biogenesis, Inc. (US) 2023-03-22 EP disclosed
CN-109310727-B Conditionally active heterodimeric polypeptides and methods of use thereof 加利福尼亚大学董事会 2022-09-27 CN disclosed
US-7972782-B2 Steroid-activated nuclear receptors and uses therefor THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2011-07-05 US disclosed
EP-2036925-A1 Novel steroid-activated nuclear receptors and uses therefor THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2009-03-18 EP disclosed
EP-1235861-B1 TRANSGENIC MOUSE EXPRESSING STEROID-ACTIVATED NUCLEAR RECEPTOR SALK INST FOR BIOLOGICAL STUDI (US) 2008-10-22 EP disclosed
US-7413853-B2 Modulation of metabolism of steroids and xenobiotics THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2008-08-19 US disclosed
EP-1051479-B1 NOVEL STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREFOR SALK INST FOR BIOLOGICAL STUDI (US) 2008-07-16 EP disclosed
US-7214482-B2 Steroid-activated nuclear receptors and uses therefor THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2007-05-08 US disclosed
US-20070026445-A1 Novel steroid-activated nuclear receptors and uses therefor THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2007-02-01 US disclosed
US-6984773-B1 Transgenic mice expressing a human SXR receptor polypeptide THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2006-01-10 US disclosed
US-20030064430-A1 NOVEL STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREFOR NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-04-03 US disclosed
US-20030044888-A1 NOVEL STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREFOR HOWARD HUGHES MEDICAL INSTITUTE 2003-03-06 US disclosed
WO-2003005812-A2 MODULATION OF METABOLISM OF STEROIDS AND XENOBIOTICS THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2003-01-23 WO disclosed
EP-1051479-A4 NOVEL STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREFOR SALK INST FOR BIOLOGICAL STUDI (US) 2002-12-04 EP disclosed
EP-1235861-A2 NOVEL STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREFOR THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2002-09-04 EP disclosed
US-6274118-B1 INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE NORDION INTERNATIONAL INC. (CA) 2001-08-14 US disclosed
WO-2001042290-A2 NOVEL STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREFOR THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2001-06-14 WO disclosed
EP-1051479-A1 NOVEL STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREFOR THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2000-11-15 EP disclosed
WO-1999035246-A9 NOVEL STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREFOR SALK INST FOR BIOLOGICAL STUDI (US) 1999-09-30 WO disclosed
WO-1999035246-A1 NOVEL STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREFOR THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1999-07-15 WO disclosed